Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEP-4199 (Sumitomo Pharma America)
- Development stage
- Unknown
- Lead developer
- Sumitomo Pharma America
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SEP-4199 is an investigational, orally administered, controlled-release formulation of a non-racemic ratio of amisulpride enantiomers, specifically 85% R-amisulpride and 15% S-amisulpride. Developed by Sumitomo Pharma America (formerly Sunovion), it is currently in Phase 3 clinical development for the treatment of major depressive episodes associated with Bipolar I disorder (bipolar depression). The drug's pharmacological profile is characterized by potent antagonism at serotonin 5-HT7 receptors and dopamine D2 and D3 receptors. By utilizing a specific ratio of enantiomers, SEP-4199 aims to provide robust antidepressant efficacy while minimizing the side effects typically associated with racemic amisulpride, such as extrapyramidal symptoms and elevated prolactin levels.
- Other names
- R-amisulpride/S-amisulpride (85:15 ratio)
02
Targets
DRD3 (Dopamine receptor D3)HTR7 (5-hydroxytryptamine receptor 7)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on SEP-4199 (Sumitomo Pharma America).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEP-4199 (Sumitomo Pharma America).